It all depends on what the issue is. And, that is why I'm waiting.
GLTA
In Reply to 'buckyboy'
I believe the merger in S. Korea caused some accounting issues for KPMG, and it is simply taking awhile to straighten the situation out. We are completely relying on Han to correct the situation which will allow AMST to move forward. Histostem just got their CEO situation straightened out on Dec 8th, so things are certainly taking awhile to reorganize on their side after the Fubit merger. The great thing is they have cash and are willing to move forward into N.America with Dwight at the helm (JMHO). There are significant shareholders in the mix who are simply holding on until the true value is unlocked. Even taking into account ACTC, I can't think of another biotech stem cell play that is as undervalued to the potential market cap as AMST. You could potentially be sitting on a 2 - 3 thousand percent return (yes I said thousand.....) once this opportunity establishes its accounting and its distribution network. Every day that passes gets us a step closer. Best wishes to all.
GLTA... KarinCA ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."